Clinical trial
Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's…
NCT00083707 · University of Arkansas, Other · Completed
Key facts
| NCT number | NCT00083707 |
|---|---|
| Title | Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia |
| Official title | UARK 99-006, A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia |
| Lead sponsor | University of Arkansas, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Waldenstrom Macroglobulinemia |
| Intervention type | Drug |
| Interventions | Thalidomide |
| Enrollment | 40 |
| Start date | Jan 1, 1999 |
| Completion | Feb 1, 2003 |
| First posted | May 31, 2004 |
| Last update posted | Jul 5, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: